Xilio Therapeutics reported a net loss of $5.95 million
Xilio Therapeutics (XLO) filed a 10-Q with the SEC on Nov 10, 2026, 7:41 am ET. Source: the filing on SEC EDGAR.
Quarterly report for the period ended Sep 30, 2026, 6 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001193125-26-454453
- Revenue: $9.98 million for the three months ended Sep 30, 2026
- Net loss: $5.95 million for the three months ended Sep 30, 2026
- Cash and equivalents: $122.18 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
6 new risk factors · 3 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change QoQ | |
|---|---|---|---|
| Revenue | $9.98M | $18.69M | −47% |
| Operating income and margin | −$11.75M · -117.7% | −$3.49M · -18.7% | −237%, margin −99 pts |
| Net income | −$5.95M | −$6.37M | +6.7% |
| Operating cash flow | −$13.79M | −$18.76M | +27% |
| Cash | $122.18M | $136.04M | −10% |
New risk factors (6)
- There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise become unavailable to offset future income tax liabilities. As described below in "Risks Related to Ownership of Our Common Stock and Our Status as a…
- We rely on third-party license agreements pursuant to which we have non-exclusive and exclusive rights to technology that is incorporated into our development programs and product candidates. These license agreements impose diligence, milestone payment, royalty payment and other obligations on us.
- "information on this page may be modified and/or removed in the future subject to the terms of the court's order and implemented consistent with applicable law." Accordingly, in light of these ongoing actions, there is considerable uncertainty surrounding the draft DAP guidance and how the FDA will consider DAPs in…
- 2026, the Consolidated Appropriations Act of 2026 was enacted into law. It overruled these court decisions and codified the FDA's longstanding interpretation of the scope of orphan drug exclusivity to apply to "the same drug for the same approved use or indication within such designated rare disease or condition."…
- Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects. Further, we cannot assure you that…
- and 1 more in the filing
Removed risk factors (3)
- We rely on third-party license agreements pursuant to which we have non-exclusive and exclusive rights to technology that is incorporated into our development programs and product candidates. For example, under our license agreement with City of Hope, we have exclusively in-licensed certain patent rights that cover…
- Under our agreement with City of Hope, we are responsible for the achievement of certain diligence milestones, and our failure to timely achieve such milestones could result in City of Hope's termination of the agreement or conversion of our exclusive licenses under the licensed patents to non-exclusive licenses. If…
- On April 2, 2026, the administration issued a proclamation invoking Section 232 of the Trade Expansion Act of 1962 to impose tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the U.S. Specifically, beginning July 31, 2026, a